Qualitative or quantitative defects of gamma-sarcoglycan

Qualitative or quantitative defects of gamma-sarcoglycan (Orphanet code 207067) refers to a group of molecular abnormalities affecting the gamma-sarcoglycan protein, encoded by the SGCG gene located on chromosome 13q12. Gamma-sarcoglycan is a critical component of the dystrophin-associated glycoprotein complex (DGC), which provides structural stability to the muscle cell membrane (sarcolemma) during contraction. When gamma-sarcoglycan is absent, reduced in quantity, or structurally abnormal, the integrity of the sarcolemma is compromised, leading to progressive muscle fiber damage and degeneration. These defects are the underlying molecular basis of Limb-Girdle Muscular Dystrophy type R5 (LGMDR5), formerly known as LGMD2C or gamma-sarcoglycanopathy. The condition primarily affects skeletal muscle, leading to progressive proximal muscle weakness predominantly involving the pelvic and shoulder girdle muscles. Onset typically occurs in childhood, often between ages 3 and 12, with symptoms including difficulty running, climbing stairs, and rising from the floor (Gowers' sign). Calf pseudohypertrophy may be present. Cardiac involvement, including dilated cardiomyopathy, can occur and may contribute to morbidity. Respiratory insufficiency may develop as the disease progresses. Serum creatine kinase levels are markedly elevated. There is currently no curative treatment for gamma-sarcoglycan deficiency. Management is supportive and multidisciplinary, including physical therapy to maintain mobility, orthopedic interventions for contractures and scoliosis, cardiac monitoring and treatment as needed, and respiratory support when indicated. Gene therapy approaches targeting SGCG are under active investigation in clinical trials and represent a promising future therapeutic avenue. Corticosteroids may be considered in some cases, though evidence is limited compared to dystrophinopathies.

Common questions about Qualitative or quantitative defects of gamma-sarcoglycan